Novartis Sale Of US Oral Generics Unit Seems Unlikely
Executive Summary
The Swiss giant's Sandoz division is exploring options for its underperforming US oral generics unit but reports that it may be considering a sale of the latter go against Novartis' previous comments and observers are struggling to see the rationale behind such a move.
You may also be interested in...
Novartis Sees The Light And Plumps For Alcon Spin-Off
Having acquired Alcon for an eye-watering $52bn seven years ago, the Swiss major has decided that spinning off the eyecare business which has finally returned to growth (but is worth about half what Novartis paid in 2011) makes the most sense as it becomes a company even more focused on pharma.
Novartis Sees The Light And Plumps For Alcon Spin-Off
Having acquired Alcon for an eye-watering $52bn seven years ago, the Swiss major has decided that spinning off the eyecare business which has finally returned to growth (but is worth about half what Novartis paid in 2011) makes the most sense as it becomes a company even more focused on pharma.
Novartis Sees The Light And Plumps For Alcon Spin-Off
Having acquired Alcon for an eye-watering $52bn seven years ago, the Swiss major has decided that spinning off the eyecare business which has finally returned to growth (but is worth about half what Novartis paid in 2011) makes the most sense as it becomes a company even more focused on pharma.